OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was pending major changes and was on hold, pending activation; administratively withdrawn; will be submitted as a new protocol if study is revised.

Conditions

Pancreatic Cancer, Metastatic

Interventions

DRUG: Gemcitabine, Erlotinib, OSI-906
DRUG: Gemcitabine, Erlotinib

Sponsor

Dana-Farber Cancer Institute